Clinical Trial Site Performance: Metrics, Benchmarks, and Improvement

Sponsors and CROs run internal performance reviews after every study closes. The clinical trial enrollment metrics they track determine which sites get offered future studies, and which do not. Most sites never see this data. This guide explains what is on that scorecard, what each metric actually signals at the site level, and what to do when any of them move in the wrong direction.

The Scorecard Sponsors Don't Share With You

After every study closes, most sponsors run a site performance review. The data lives in their clinical operations team, sometimes in a CRO's vendor management system, and occasionally in a formal preferred site program. Sites that perform well get invited back. Sites that underperform often stop receiving inquiries, with no explanation.

The metrics driving these decisions are not proprietary. They are standard across the industry. But they are rarely communicated back to sites in a way that allows for course correction. What follows is a breakdown of the five metrics that appear on nearly every sponsor performance review, along with what each one actually signals at the site level.

A note on where evaluation starts: before a site is assessed on enrollment, it is assessed on fit. A thorough feasibility assessment before committing to a protocol is the earliest signal sponsors have about whether a site understands its own patient population.

Enrollment Rate: The Number Everyone Watches First

Enrollment rate measures how many patients a site randomizes per month against the target set at study activation. Sponsors calculate this at the site level, not just across the full study, which means underperformance at one site is visible even when the overall trial appears on track.

What constitutes a strong enrollment rate varies by phase and indication. A Phase 1 oncology trial with tight eligibility runs differently from a Phase 2 vaccine study with broad inclusion criteria. What stays consistent is how your site's rate compares to every other site on the same protocol.

The most common cause of a declining enrollment rate mid-study is not a patient availability problem. It is a pre-screening breakdown: patients who should have been disqualified early move too far through the process, consuming coordinator time without reaching randomization. If your enrollment rate is slower than projected and your screen fail rate is also elevated, that is where to look first.

For a detailed breakdown of the patterns that push sites below their targets, see why sites miss enrollment goals. 53% of clinical studies have experienced extended timelines, and one in six has taken more than twice as long as originally planned (Credevo). Enrollment rate is the leading indicator for which category a study falls into.

Screen Fail Rate: The Metric That Damages Reputations

Screen fail rate is the ratio of patients screened to patients randomized. If 20 patients are screened and 5 are randomized, the screen fail rate is 75%.

A high screen fail rate is one of the most visible signals that a site is not pre-screening effectively. Sponsors interpret it one of two ways: the site does not know its own patient population well enough to qualify candidates before screening begins, or the site's patient pool is not a genuine match for the protocol. Neither interpretation is useful for the site's standing.

Rates above 60–70% in non-rare disease trials tend to trigger sponsor review. The fix at most sites is simpler than it appears: a pre-screen checklist reviewed with the coordinator before each patient contact, and an honest audit of whether the site's patient database reflects the actual eligibility criteria. Sites that run detailed feasibility reviews before study activation enter studies with lower screen fail rates from the start.

Time to First Patient: The Startup Signal Sponsors Remember

Time to first patient enrolled (also called First Patient In, or FPI) measures how long a site takes to go from initiation to randomizing the first participant. Sponsors track this because delayed startup shifts the entire trial timeline.

A site that activates quickly signals operational readiness. One that takes two or three months after initiation to enroll the first patient signals the opposite, regardless of how well enrollment performs later. Three factors account for most FPI delays at the site level.

Retention Rate and Protocol Deviation Frequency

Patient dropout and protocol deviations are both tracked at the site level. Neither affects enrollment numbers directly. Both affect whether the data a site generates is usable, and both inform sponsor decisions about future study allocation.

Retention rate measures what percentage of enrolled patients complete the study. High dropout rates signal a patient experience problem: visits are too burdensome, coordinator communication is inconsistent, or patients did not fully understand the time commitment at consent. Sites with chronic retention problems are less likely to receive long-duration protocols.

Protocol deviation frequency is a data quality signal. Frequent deviations (missed visits, incorrect dosing windows, improperly collected samples) suggest staff training gaps. One or two deviations over a long protocol are expected. A pattern of deviations at a single site is a flag in sponsor review.

Both are lagging indicators. By the time a pattern appears in sponsor reporting, the study is already affected. A site-side audit at the 25% enrollment mark, reviewing dropout reasons and deviation logs, gives enough lead time to intervene before the pattern becomes visible externally.

How Sponsors Use These Metrics to Allocate Future Studies

Performance data does not stay within one study. It follows a site across CRO relationships, across sponsors, and across years. A site that underperformed on enrollment rate for one protocol is unlikely to be the first call when the same sponsor's next study opens, even if a different CRO is managing the relationship.

Preferred site programs formalize this process. Sites that consistently meet enrollment targets, activate quickly, and deliver clean data get flagged in sponsor systems as high-performance sites. They receive earlier study inquiries, more favorable budget negotiations, and access to protocols with higher per-patient fees.

For sites without an existing sponsor relationship, performance in similar indications becomes the entry point. A strong enrollment feasibility report is often the first evidence a site presents that it is worth a formal site qualification visit. Sites with documented performance in comparable protocols have a clear advantage at that stage.

Building a Performance Dashboard for Your Site

Most sites do not track their own metrics in any structured way. Enrollment progress lives in a spreadsheet. Screen fail data surfaces when the sponsor requests a report. Retention numbers appear when a patient drops out and the coordinator updates the log.

A simple internal dashboard does not require a CTMS. Five metrics, reviewed monthly by site leadership, provide enough visibility to catch problems before they reach sponsor review.

Monthly review of these five numbers, shared between site director and lead coordinator, gives your site the same visibility into its own performance that your sponsors already have.